Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells

Anti-Cancer Drugs

Volumn 25, Issue 1, 2014, Pages 72-81

  Andrade, Augusto F ^a   Borges, Kleiton S ^a   Castro Gamero, Angel M ^a   Silveira, Vanessa S ^a   Suazo, Veridiana K ^a   Oliveira, Jaqueline C ^a   Moreno, Daniel A ^a   De Paula Queiroz, Rosane G ^a   Scrideli, Carlos A ^a   Tone, Luiz G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute lymphoblastic leukemia; DNA methyltransferases inhibitor; Methylation; Zebularine

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BISULFITE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; METHOTREXATE; VINCRISTINE; ZEBULARINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIZATION; CHILDHOOD CANCER; CLONOGENESIS; CYTOTOXICITY; DNA METHYLATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL; PRIORITY JOURNAL; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CYTIDINE; DNA MODIFICATION METHYLASES; DRUG ANTAGONISM; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; METHOTREXATE; METHYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ARYL HYDROCARBON; VINCRISTINE;

EID: 84889238806     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000028     Document Type: Article

References (50)

1. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr 2009; 21:1-8.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-178. (Pubitemid 43076714)
3. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008; 22:1529-1538.
4. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010; 115:1214-1225.
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
6. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003; 63:1114-1121. (Pubitemid 36278446)
7. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-3229. (Pubitemid 32695003)
8. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 50 CpG island methylation in acute leukemia. Clin Cancer Res 2000; 6:4243-4248.
9. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005; 17:55-60. (Pubitemid 40179913)
10. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphoblastic leukemia independently of its methylated status. J Clin Oncol 2005; 23:3932-3939. (Pubitemid 46218696)
11. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004; 24:1270-1278. (Pubitemid 38112188)
12. Christman JK. 5-Azacytidine and 5-aza-20-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21:5483-5495. (Pubitemid 34983483)
13. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123:8-13. (Pubitemid 351705186)
14. Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249:135-164. (Pubitemid 30134342)
15. Marquez VE, Barchi JJ Jr, Kelley JA, Liang G, Xu GL, Hu YG, et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 2005; 24:305-318. (Pubitemid 41440605)
16. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002; 321:591-599. (Pubitemid 36124798)
17. Yoo CB, Chuang JC, Byun HM, Egger G, Yang AS, Dubeau L, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) 2008; 1:233-240.
18. van Bemmel DM, Brank AS, Eritja R, Marquez VE, Christman JK. DNA (cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem Pharmacol 2009; 78:633-641.
19. Suzuki M, Shinohara F, Endo M, Sugazaki M, Echigo S, Rikiishi H. Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2009; 64:223-232.
20. Meador JA, Su Y, Ravanat JL, Balajee AS. DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by zebularine. Carcinogenesis 2010; 31:184-191.
21. Rao SP, Rechsteiner MP, Berger C, Sigrist JA, Nadal D, Bernasconi M. Zebularine reactivates silenced E-cadherin but unlike 5-azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol Cancer 2007; 6:3.
22. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 2007; 35:263-273. (Pubitemid 46135814)
23. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005; 4:1505-1514. (Pubitemid 41556432)
24. Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol 2007; 31:1449-1456.
25. Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, et al. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 2012; 138:405-414.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-408. (Pubitemid 34164012)
28. Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz M, Ballestar E, Fraga MF, Ropero S, et al. The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 2006; 27:1099-1104.
29. Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect 2007; 115:138-145. (Pubitemid 46050296)
30. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95:399-409. (Pubitemid 36395260)
31. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-20- deoxycytidine efficacy in human prostate cancer cells. PLoS One 2011; 6:e25634.
32. Chen M, Voeller D, Marquez VE, Kaye FJ, Steeg PS, Giaccone G, et al. Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. Int J Oncol 2010; 37:963-971.
33. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-Osthoff K, Ruiz-Ruiz C. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer 2012; 130:1195-1207.
34. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-2614.
35. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2010; 120:581-592.
36. Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-20-deoxycytidine. Cancer Chemother Pharmacol 2009; 63:411-416.
37. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49:92-104. (Pubitemid 36469805)
38. Schipper RG, van den Heuvel LP, Verhofstad AA, De Abreu RA. Polyamines and DNA methylation in childhood leukaemia. Biochem Soc Trans 2007;(Pt 2):331-335. (Pubitemid 46596502)
39. Simile MM, Pascale R, De Miglio MR, Nufris A, Daino L, Seddaiu MA, et al. Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Ha-ras, and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis. Cancer Lett 1994; 79:9-16. (Pubitemid 24146715)
40. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-265. (Pubitemid 38525281)
41. Sui M, Fan W. Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 2005; 61:1151-1158. (Pubitemid 40340910)
42. Kumar KS, Sonnemann J, Hong le TT, Buurman C, Adler F, Maass M, et al. Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 2007;(1A):465-470. (Pubitemid 46363367)
43. Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, et al. Scheduledependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Invest New Drugs 2012; 30:223-235.
44. Thurmond TS, Staples JE, Silverstone AE, Gasiewicz TA. The aryl hydrocarbon receptor has a role in the in vivo maturation of murine bone marrow B lymphocytes and their response to 2,3,7,8-tetrachlorodibenzop- dioxin. Toxicol Appl Pharmacol 2000; 165:227-236. (Pubitemid 30429906)
45. Ge NL, Elferink CJ. A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J Biol Chem 1998; 273:22708-22713. (Pubitemid 28399842)
46. Ito T, Tsukumo S, Suzuki N, Motohashi H, Yamamoto M, Fujii-Kuriyama Y, et al. A constitutively active arylhydrocarbon receptor induces growth inhibition of jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest. J Biol Chem 2004; 279:25204-25210. (Pubitemid 38756771)
47. Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, et al. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 2003; 300:128-134. (Pubitemid 36042940)
48. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 2005; 70:121-133. (Pubitemid 40797876)
49. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005; 11:4571-4579. (Pubitemid 40825648)
50. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6:151-158. (Pubitemid 39485687)